Hidroclorotiazida Sandoz (Hydrochlorothiazide)

Hidroclorotiazida Sandoz is indicated for several conditions where excess fluid or high blood pressure requires pharmacologic control and fluid overload reduction.

• Hypertension, including primary and secondary forms.
• Edema associated with chronic heart failure.
• Edema due to liver cirrhosis (ascites).
• Edema related to renal disease such as nephrotic syndrome.
• Adjunct therapy for resistant hypertension when monotherapy is insufficient.
• Combination with other antihypertensive agents as part of a multi‑drug regimen.

• Hydrochlorothiazide inhibits the Na⁺/Cl⁻ symporter located in the distal convoluted tubule of the nephron. By blocking this transporter, it reduces reabsorption of sodium and chloride, leading to increased excretion of sodium, chloride, and water. The resulting decrease in extracellular fluid volume lowers cardiac output and peripheral vascular resistance, contributing to a reduction in arterial blood pressure. The diuretic effect also promotes modest potassium loss, which may be clinically relevant.

Like other thiazide diuretics, Hidroclorotiazida Sandoz can cause a range of adverse reactions. Most are mild, dose‑related, and reversible, but some may be severe and require prompt medical evaluation. Patients should be aware of both common and less frequent serious effects.

Common

• Increased urination, which may lead to mild dehydration if fluid intake is insufficient.
• Dizziness or light‑headedness, especially when standing quickly.
• Low potassium levels (hypokalemia) that can cause muscle cramps or weakness.

Serious

• Severe electrolyte imbalance such as hyponatremia or marked hypokalemia, potentially causing cardiac arrhythmia.
• Acute kidney injury manifested by reduced urine output and rising creatinine.
• Allergic reactions including skin rash, pruritus, or angioedema that may affect breathing.

Before initiating Hidroclorotiazida Sandoz, clinicians should evaluate several safety considerations to minimize risk.

• Assess renal function; avoid use in severe impairment.
• Monitor serum electrolytes, especially potassium and sodium, during therapy.
• Use cautiously in patients with gout or a history of hyperuricemia.
• Avoid during pregnancy unless benefits clearly outweigh potential risks.
• Review concomitant medications that may alter fluid or electrolyte balance.
• Adjust dose in elderly patients due to increased sensitivity.
• Counsel patients to rise slowly from sitting or lying positions to reduce orthostatic hypotension.

Hydrochlorothiazide may interact with other medicines, altering its effectiveness or increasing the likelihood of adverse effects.

Avoid

• Lithium – concurrent use can raise lithium levels and precipitate toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt the diuretic response and reduce sodium loss.
• ACE inhibitors or ARBs combined with high‑dose potassium supplements – increase risk of hyperkalemia.

Use with caution

• Antidiabetic agents – thiazide‑induced hypokalemia may enhance insulin resistance; glucose monitoring may be needed.
• Cardiac glycosides (e.g., digoxin) – electrolyte shifts can increase digoxin toxicity.
• Corticosteroids – additive fluid loss may exacerbate dehydration.
• Anticoagulants – altered plasma protein binding may affect anticoagulant levels.